Pfizer: Profile of Sasanlimab Was Generally Consistent With Reported Safety Profile of Pd-1 Inhibitors
辉瑞:萨萨利木单抗的特征与已报告的PD-1抑制剂的安全性特征基本一致
Pfizer: Profile of Sasanlimab Was Generally Consistent With Reported Safety Profile of Pd-1 Inhibitors
辉瑞:萨萨利木单抗的特征与已报告的PD-1抑制剂的安全性特征基本一致
使用浏览器的分享功能,分享给你的好友吧